This is the first report of an efficient and simple means of generating human neuronal cells for ionotropic Ro 61-8048 chemical structure receptor assays and ultimately for electrically active human neural cell assays for drug discovery. Published by Elsevier Ltd on behalf of
IBRO.”
“Objective: All current aortic endografts depend on proximal and distal fixation to prevent migration. However, migration and rupture can occur, particularly in patients with aortic necks that are short or angulated, or both. We present our initial clinical experience with a new sac-anchoring endoprosthesis designed to anchor and seal the device within the aneurysm sac.
Methods: The initial worldwide experience using a new endoprosthesis for the treatment of aortic
aneurysms (Nellix Endovascular, Palo Alto, Calif) was reviewed. The endoprosthesis consists of dual balloon-expandable endoframes surrounded by polymer-filled endobags designed to obliterate the aneurysm sac and maintain endograft position. Clinical selleck results and follow-up contrast computed tomography (CT) scans at 30 days and 6 and 12 months were reviewed.
Results: The endograft was successfully deployed in 21 patients with infrarenal aortic aneurysms measuring 5.7 +/- 0.7 cm (range, 4.3-7.4 cm). Two patients with common iliac aneurysms were treated with sac-anchoring extenders that maintained patency of the internal iliac artery. Infusion of 71 +/- 37 mL of polymer (range, 19-158 mL) into the aortic endobags resulted in complete aneurysm exclusion in all patients. Mean implant time was
76 +/- 35 minutes, with 33 +/- 17 minutes Protein kinase N1 of fluoroscopy time and 180 +/- 81 mL of contrast; estimated blood loss was 174 +/- 116 mL. One patient died during the postoperative period (30-day mortality, 4.8%), and one died at 10 months from non-device-related causes. During a mean follow-up of 8.7 +/- 3.1 months and a median of 6.3 months, there were no late aneurysm- or device-related adverse events and no secondary procedures. CT imaging studies at 6 months and 1 year revealed no increase in aneurysm size, no device migration, and no new endolcaks. One patient had a limited proximal type I endoleak at 30 days that resolved at 60 days and remained sealed. One patient has an ongoing distal type I endoleak near the iliac bifurcation, with no change in aneurysm size at 12 months.
Conclusion: Initial clinical experience with this novel intrasac anchoring prosthesis is promising, with successful aneurysm exclusion and good short-term results. This new device platform has the potential to address the anatomic restrictions and limitations of current endografts. Further studies with a longer follow-up time are needed. (J Vasc Surg 2011;53:574-82.